Press release
Desmoid Tumors Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | AFT Pharma, Timber Pharma, SpringWorks Therapeutics, Iterion Therapeutics
The Desmoid Tumors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Desmoid Tumors Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/desmoid-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Desmoid Tumors Market.
Some of the key takeaways from the Desmoid Tumors Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Desmoid Tumors treatment therapies with a considerable amount of success over the years. Desmoid Tumors Key players such as - SpringWorks Therapeutics, Immunome/Ayala Pharmaceuticals, Iterion Therapeutics, Eisai and PRISM BioLab, MedPacto, Inc., Pfizer, Novartis, Ayala Pharmaceuticals, Iterion Therapeutics, Aadi Bioscience, Inc., INSYS Therapeutics Inc, Recursion Pharmaceuticals Inc, and others, are developing therapies for the Desmoid Tumors treatment
*
Desmoid Tumors Emerging therapies such as - OGSIVEO (nirogacestat), AL102, Tegavivint (BC2059), E7386, Vactosertib, Sirolimus, Imatinib, AL102, Tegavivint, Nab-Rapamycin, Fentanyl sublingual spray, REC-4881, and others are expected to have a significant impact on the Desmoid Tumors market in the coming years.
*
In March 2024, Immunome, Inc. (Nasdaq: IMNM), a biotechnology firm dedicated to creating innovative targeted cancer therapies, announced the successful acquisition of AL102 and the related drug candidate AL101 from Ayala Pharmaceuticals, Inc.
*
In June 2025, SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company specializing in rare diseases and cancer, announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of nirogacestat. This oral gamma secretase inhibitor is proposed as a monotherapy for adults with progressing desmoid tumors in need of systemic therapy. The recommendation now moves to the European Commission (EC), which is expected to issue a final decision on the approval during the third quarter of 2025.
Get a Free Sample PDF Report to know more about Desmoid Tumors Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/desmoid-tumors-pipeline-insight [https://www.delveinsight.com/report-store/desmoid-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Desmoid Tumors Overview
Desmoid tumors, also known as aggressive fibromatosis, are rare, non-metastatic but locally invasive tumors that arise from the connective tissue, which includes tendons and ligaments. Although they do not spread to distant organs, desmoid tumors can be very aggressive locally and can recur after surgical removal.
Emerging Desmoid Tumors Drugs Under Different Phases of Clinical Development Include:
*
OGSIVEO (nirogacestat): SpringWorks Therapeutics
*
AL102: Immunome/Ayala Pharmaceuticals
*
Tegavivint (BC2059): Iterion Therapeutics
*
E7386: Eisai and PRISM BioLab
*
Vactosertib: MedPacto, Inc.
*
AL102: Ayala Pharmaceuticals
*
Tegavivint: Iterion Therapeutics
*
Sirolimus: Pfizer
*
Imatinib: Novartis
*
Nab-Rapamycin: Aadi Bioscience, Inc.
*
Fentanyl sublingual spray: INSYS Therapeutics Inc
*
REC-4881: Recursion Pharmaceuticals Inc
Route of Administration
Desmoid Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Intravenous
*
Subcutaneous
*
Parenteral
*
Topical
Molecule Type
Products have been categorized under various Molecule types, such as
*
Recombinant fusion proteins
*
Small molecule
*
Monoclonal antibody
*
Peptide
*
Polymer
*
Gene therapy
Desmoid Tumors Pipeline Therapeutics Assessment
*
Desmoid Tumors Assessment by Product Type
*
Desmoid Tumors By Stage and Product Type
*
Desmoid Tumors Assessment by Route of Administration
*
Desmoid Tumors By Stage and Route of Administration
*
Desmoid Tumors Assessment by Molecule Type
*
Desmoid Tumors by Stage and Molecule Type
DelveInsight's Desmoid Tumors Report covers around 4+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Desmoid Tumors product details are provided in the report. Download the Desmoid Tumors pipeline report to learn more about the emerging Desmoid Tumors therapies [https://www.delveinsight.com/sample-request/desmoid-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Desmoid Tumors Therapeutics Market include:
Key companies developing therapies for Desmoid Tumors treatment are - SpringWorks Therapeutics, Iterion Therapeutics, Cellestia Biotech, BioSpecifics Technologies Corp., 180 Life Sciences, AFT Pharma, Timber Pharmaceuticals, MedPacto, Intas Pharmaceuticals, Jina pharmaceuticals, and others
Desmoid Tumors Pipeline Analysis:
The Desmoid Tumors pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Desmoid Tumors with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Desmoid Tumors Treatment.
*
Desmoid Tumors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Desmoid Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Desmoid Tumors market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Desmoid Tumors drugs and therapies [https://www.delveinsight.com/sample-request/desmoid-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Desmoid Tumors Pipeline Market Drivers
*
No licensed therapy for Desmoid Tumor, which presents an opportunity for pharmaceutical companies to enter the market
*
Market growth of Desmoid Tumors will be boosted by increased R&D and the anticipated introduction of new therapies
Desmoid Tumors Pipeline Market Barriers
*
There are challenges in conducting rare cancer clinical trials due to issues surrounding clinical trial design, patient recruitment, and analysis
*
Lack of approved therapies poses a significant burden on Desmoid Tumors patients
*
Owing of its rarity, Desmoid Tumors poses research obstacles, and only a few attempts have been made to develop medications for the condition
Scope of Desmoid Tumors Pipeline Drug Insight
*
Coverage: Global
*
Key Desmoid Tumors Companies: SpringWorks Therapeutics, Immunome/Ayala Pharmaceuticals, Iterion Therapeutics, Eisai and PRISM BioLab, MedPacto, Inc., Pfizer, Novartis, Ayala Pharmaceuticals, Iterion Therapeutics, Aadi Bioscience, Inc., INSYS Therapeutics Inc, Recursion Pharmaceuticals Inc, and others
*
Key Desmoid Tumors Therapies: OGSIVEO (nirogacestat), AL102, Tegavivint (BC2059), E7386, Vactosertib, Sirolimus, Imatinib, AL102, Tegavivint, Nab-Rapamycin, Fentanyl sublingual spray, REC-4881, and others
*
Desmoid Tumors Therapeutic Assessment: Desmoid Tumors current marketed and Desmoid Tumors emerging therapies
*
Desmoid Tumors Market Dynamics: Desmoid Tumors market drivers and Desmoid Tumors market barriers
Request for Sample PDF Report for Desmoid Tumors Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/desmoid-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1
Desmoid Tumors Report Introduction
2
Desmoid Tumors Executive Summary
3
Desmoid Tumors Overview
4
Desmoid Tumors- Analytical Perspective In-depth Commercial Assessment
5
Desmoid Tumors Pipeline Therapeutics
6
Desmoid Tumors Late Stage Products (Phase II/III)
7
Desmoid Tumors Mid Stage Products (Phase II)
8
Desmoid Tumors Early Stage Products (Phase I)
9
Desmoid Tumors Preclinical Stage Products
10
Desmoid Tumors Therapeutics Assessment
11
Desmoid Tumors Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Desmoid Tumors Key Companies
14
Desmoid Tumors Key Products
15
Desmoid Tumors Unmet Needs
16
Desmoid Tumors Market Drivers and Barriers
17
Desmoid Tumors Future Perspectives and Conclusion
18
Desmoid Tumors Analyst Views
19
Appendix
20
About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=desmoid-tumors-pipeline-2025-latest-fda-approvals-clinical-trials-and-emerging-therapies-assessment-by-delveinsight-aft-pharma-timber-pharma-springworks-therapeutics-iterion-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Desmoid Tumors Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | AFT Pharma, Timber Pharma, SpringWorks Therapeutics, Iterion Therapeutics here
News-ID: 4083675 • Views: …
More Releases from ABNewswire
Blessed Transportation Expands 24/7 Bus Charter Operations Throughout Renton and …
Blessed Transportation expands its 24-hour luxury transportation services throughout Renton and Seattle, leveraging over 22 years of experience, comprehensive licensing, and family-owned business values that distinguish it as a professional charter operation in Northwest Washington.
The Pacific Northwest transportation industry is experiencing significant enhancements with Blessed Transportation's announcement of expanded 24-hour bus charter operations and luxury fleet services throughout Renton, Seattle, and surrounding Washington communities. The family-owned transportation company continues to…
Vedder Roofing & Construction Earns Praise for Seamless Roofing Replacement Proj …
Vedder Roofing & Construction has become a name synonymous with professionalism and seamless service. Known for their attention to detail and consistent quality, the company has earned widespread recognition for its exceptional roofing replacement projects.
In the world of home maintenance, few investments are as critical as a sturdy and well-functioning roof. Over time, exposure to wind, rain, sun, and seasonal changes can wear down even the best-built roofs, making replacement…
New Heights in Home Protection: Vedder Roofing & Construction's Roof Installatio …
In an industry where quality and precision matter, Vedder Roofing & Construction has emerged as a reliable name for homeowners seeking dependable and high-standard roof installation solutions. With a strong reputation built on experience, integrity, and craftsmanship, the company continues to elevate standards in residential roofing.
A roof is one of the most critical components of any home, serving as the primary shield against the elements and playing a key role…
Women in Manufacturing NY Hosts "Powering the Future" Summit at Brooklyn Navy Ya …
Image: https://www.abnewswire.com/upload/2025/06/7983667b711324f4f387cd5e0fe7a63a.jpg
Image courtesy of 90 Plus Media Group.
On June 13, 2025, Women in Manufacturing New York (WIMNY), in collaboration with Community Architects, hosted a high-impact summit titled "Powering the Future: Workforce, Innovation, and Manufacturing" at Newlab, located in the heart of the Brooklyn Navy Yard. The convening brought together manufacturers, workforce leaders, educators, public officials, and students to explore how cross-sector partnerships can strengthen career-connected learning and ensure inclusive access…
More Releases for Desmoid
Desmoid Tumor Treatment Market by Market Trends, Active Modernization in Technol …
It is an objective of every organization to achieve the set profit goals and this Desmoid Tumor Treatment market report helps key players in this regard by providing finest market tactics as well as enable them to attain larger revenues in the business. Measuring present success level is also easy with the help of this market report. Functional areas of business are covered here. Business tactics provided here will…
Desmoid Tumor Market Size 2021 | Incredible Possibilities of Growth and Opportun …
Desmoid tumor, also called aggressive fibromatosis, often occurs in the legs, arms, and abdomen. These tumors are noncancerous growths that occur in the human connective tissue. Since these tumors are noncancerous, they do not spread to other body parts; however, they can be aggressive and grow into nearby organs and structures. The common symptoms associated with desmoid tumors include an area or mass of swelling, loss of function in that…
Desmoid Tumor Market Growing Dynamically with Leading Top Key Players like Amgen …
Desmoid tumor, also called aggressive fibromatosis, often occurs in the legs, arms, and abdomen. These tumors are noncancerous growths that occur in the human connective tissue.
Since these tumors are noncancerous, they do not spread to other body parts; however, they can be aggressive and grow into nearby organs and structures.
The common symptoms associated with desmoid tumors include an area or mass of swelling, loss of function in that…
Desmoid Tumors Market to show vigorous growth with industry’s leading players …
Desmoid Tumors Market Top Key Players
Some of key the players in the market are Amgen Inc., Novartis AG, Abbott Laboratories, Bayer AG, AbbVie Inc., Beckman Coulter Inc., Stryker Corporation, Debiopharm Group, F. Hoffmann-La Roche Ltd, and others.
Market Scenario
Desmoid tumors are also known as desmoid fibromatosis. These benign growths occur very rarely in the general population. Desmoid tumor usually develops in the fibrous tissue of the body, commonly in the…
Desmoid Tumors Market Market Overview, Leading Players-Amgen Inc., Novartis AG, …
Market Scenario
Desmoid tumors are also known as desmoid fibromatosis. These benign growths occur very rarely in the general population. Desmoid tumor usually develops in the fibrous tissue of the body, commonly in the arms, legs or midsection, and sometimes in the head and neck. The term desmoid was derived from the Greek word desmos, which means tendonlike. Desmoid tumors appear as well-differentiated, and firm overgrowths of fibrous tissue. According to…
Global Desmoid Tumors Market 2018 Major Key Companies – Beckman Coulter Inc., …
Market Scenario
Desmoid tumors are also known as desmoid fibromatosis. These benign growths occur very rarely in the general population. Desmoid tumor usually develops in the fibrous tissue of the body, commonly in the arms, legs or midsection, and sometimes in the head and neck. The term desmoid was derived from the Greek word desmos, which means tendonlike. Desmoid tumors appear as well-differentiated, and firm overgrowths of fibrous tissue. According to…
